Researchers from A*STAR’S Genome Institute of Singapore (GIS) and Nanyang Technological University have successfully developed iCas, a new Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) protein capable of more accurately altering the DNA of cells with minimal unintended modifications, one of the major problems with the existing CRISPR-Cas1 gene-cutting method. On the other hand, iCas will remain off in the absence of tamoxifen. The researchers used an engineered version of CRISPR to cut out two genes that are important for making proteins called RNA polymerase.
Researchers from A*STAR’S Genome Institute of Singapore (GIS) and Nanyang Technological University have successfully developed iCas, a new Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) protein capable of more accurately altering the DNA of cells with minimal unintended modifications, one of the major problems with the existing CRISPR-Cas1 gene-cutting method. The researchers used an engineered version of CRISPR to cut out two genes that are important for making proteins called RNA polymerase.